FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 17654 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| The efficacy of early progressive resistance exercise in the postoperative management of pancreaticoduodenectomy for pancreatic cancer: a randomized controlled trial. PMID 40822270 · Front Surg · 2025 The study is a randomized controlled trial in pancreatic cancer surgery evaluating an exercise intervention, but it lacks a drug intervention and does not report any time-to-event efficacy endpoints like OS, PFS, DFS, etc. It focuses on recovery metrics and quality of life. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| The 96-week outcomes and pharmacokinetics of long-acting cabotegravir plus rilpivirine in South Africans. PMID 40801059 · South Afr J HIV Med · 2025 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
|
仅历史库存 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Ipilimumab with temozolomide vs. temozolomide alone after surgery and chemoradiotherapy in recently diagnosed glioblastoma: a randomized phase II clinical trial. PMID 40800123 · Neurooncol Adv · 2025 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Randomized Controlled Trial Comparative Study in Powered and Manual Stapler in Low Anterior Resection of Rectal Cancer. PMID 40798889 · Asian J Endosc Surg · 2025 The study is a randomized controlled trial in rectal cancer patients comparing two surgical staplers, not a drug intervention. It does not report a time-to-event efficacy endpoint such as OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR; the primary outcome is anastomotic leakage (a complication), with logistic regression analysis. Therefore, it does not meet the criteria for inclusion in the oncology Kaplan-Meier digitization cohort. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Impact of first-line chemoimmunotherapy with or without radiotherapy on the prognosis of patients with locally advanced or metastatic esophageal squamous cell carcinoma: a multicenter, real-world, retrospective cohort study from China (NCT06478355). PMID 40791599 · Front Immunol · 2025 The study is a retrospective real-world analysis and does not meet the requirement for a Phase III/IIIb or Phase II/III randomized trial. Therefore, it is excluded. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Dynamic circulating tumor DNA indicates pathological benefits of additional neoadjuvant chemoimmunotherapy courses for locally advanced non-small-cell lung cancer patients. PMID 40777124 · Front Oncol · 2025 The record describes a subgroup analysis from a Phase III randomized trial in NSCLC evaluating neoadjuvant chemoimmunotherapy cycles. While it is oncologic, human, randomized, Phase III, and drug-intervening, the primary endpoint reported is pathological complete response (pCR), a binary pathological outcome, not a time-to-event efficacy endpoint (e.g., OS, PFS, DFS). The analysis is explicitly a subgroup analysis based on ctDNA-MRD status. Therefore, it does not meet the inclusion criteria for a time-to-event primary/key secondary endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of peripherally-restricted κ-opioid receptor agonist-HSK21542 for postoperative analgesia in patients undergoing laparoscopic abdominal surgery: a randomized, placebo-controlled phase 2 trial. PMID 40776930 · Front Med (Lausanne) · 2025 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Comparison of endoscopic and endoscope-assisted microscopic transsphenoidal surgery for pituitary adenoma resection: a prospective randomized study. PMID 40766292 · Front Endocrinol (Lausanne) · 2025 Study compares surgical techniques for pituitary adenoma, lacks drug intervention, and does not report time-to-event efficacy endpoints like OS or PFS with Kaplan-Meier or HR. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Analysis of control arms in oncology randomised trials in Brazil: a cross-sectional study. PMID 40765840 · BMJ Oncol · 2025 This is a cross-sectional methodological study analyzing control arms of trials, not an original report of a single trial's efficacy results. It does not present time-to-event efficacy data (OS, PFS, etc.) from a specific trial. The drug intervention criterion cannot be established from this secondary analysis. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Acceptability and implementation potential of a health literacy intervention to increase colorectal cancer screening in deprived areas: A qualitative study of patients and general practitioners participating in a cluster randomized controlled trial. PMID 40763131 · PLoS One · 2025 The record is a qualitative study of a health literacy intervention for colorectal cancer screening. While it is from a randomized controlled trial (cluster RCT), it does not meet key eligibility criteria: it lacks a drug-containing intervention, no time-to-event efficacy endpoint is reported, and the phase is not established as Phase III/IIIb or Phase II/III. The study reports patient and provider acceptability, not efficacy outcomes. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Cost-effectiveness analysis of cadonilimab plus chemotherapy as a first-line treatment option in HER-2-negative advanced gastric cancer. PMID 40761936 · Front Public Health · 2025 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
S
B
|
严格 v3 独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Brucea javanica oil emulsion plus supportive care for refractory advanced colorectal cancer: a pilot RCT protocol. PMID 40761400 · Front Pharmacol · 2025 The record is a protocol for a future trial, not an original result report of a completed randomized trial with a drug intervention and time-to-event efficacy endpoint. |
H
S
B
|
严格 v3 独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Exploratory unsupervised machine learning of angiogenesis biomarkers in a phase II advanced cervical cancer trial of radiochemotherapy with or without neoadjuvant chemotherapy. PMID 40743651 · Clinics (Sao Paulo) · 2025 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Non-Randomized Controlled Trial Comparing Response of Rectal Cancer Chemoradiation with and without Low-Dose Aspirin. PMID 40740570 · Med J Islam Repub Iran · 2025 The study is a non-randomized controlled trial (explicitly stated in title and methods), which excludes it from being a randomized trial. The phase is not specified, and there is no indication it is Phase III/IIIb. The primary endpoint is pathological complete response (pCR), which is not a time-to-event efficacy endpoint. No time-to-event data (OS, PFS, DFS, EFS, RFS, TTP), Kaplan-Meier curves, or hazard ratios are reported. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Hypofractionated radiotherapy for head and neck squamous cell carcinoma. PMID 40737737 · Cancer Radiother · 2025 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Effectiveness of Remote High-Intensity Aerobic Interval Training on Quality of Life and Physical Health in Breast Cancer Survivors: Two Years Follow-Up. PMID 40735810 · Integr Cancer Ther · 2025 Study is an oncology, human, randomized controlled trial reporting original results. However, it does not meet key eligibility criteria: the intervention is non-drug-only (exercise), there is no time-to-event efficacy endpoint (OS, PFS, etc.), the phase is not explicitly stated as III/IIIb, and the primary endpoint is quality of life/physical health (not time-to-event efficacy). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Effectiveness of a Care Plan Based on the Multi-Theory Model in Reducing Fear of Disease Progression and Improving Quality of Life in Breast Cancer Patients: A Randomized Controlled Trial. PMID 40735051 · Breast Cancer (Dove Med Press) · 2025 The study is a randomized controlled trial in breast cancer patients receiving adjuvant chemotherapy, but it does not report a time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP) or Kaplan-Meier/HR results. The primary outcomes are psychological and quality-of-life measures (fear of progression, quality of life, self-management efficacy). The phase is not specified in the provided metadata. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Pancreatoduodenectomy versus total pancreatectomy and simultaneous intraportal islet autotransplantation for periampullary cancer at high-risk of postoperative pancreatic fistula (XANDTX-trial): Protocol of a randomized controlled pilot trial. PMID 40720532 · PLoS One · 2025 Excluded because it is a protocol (no results), lacks a drug-containing intervention, and does not establish a primary/key secondary time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Patient experience with familial chylomicronemia syndrome before and after olezarsen treatment: Qualitative interviews with clinical trial participants. PMID 40713231 · J Clin Lipidol · 2025 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Sample Size for Enriched Biomarker Designs With Measurement Error for Time-to-Event Outcomes. PMID 40711765 · Pharm Stat · 2025 The record describes a methodological article on sample size calculation for enriched biomarker designs in oncology trials. It is not an original report of a Phase III randomized trial's results with a drug-containing intervention and a time-to-event efficacy endpoint. The article is eligible for exclusion based on its type (methodology/design paper) and lack of original trial result reporting. |
H
S
B
|
严格 v3 独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Oligometastatic head and neck cancer: Navigating patient trajectories and broader implications. PMID 40706555 · Cancer Radiother · 2025 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Cost-effectiveness analysis of sintilimab additional to chemoradiotherapy in high-risk locoregionally advanced nasopharyngeal carcinoma. PMID 40703356 · Front Pharmacol · 2025 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
S
B
|
严格 v3 独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Time-in-Range Analysis of Responses after Intravitreal Dexamethasone Therapy in Eyes with Diabetic Macular Edema. PMID 40688490 · Ophthalmol Sci · 2025 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
|
仅历史库存 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Comparison of anlotinib combined with docetaxel versus single docetaxel as second-line treatment beside radiotherapy for advanced non-small cell lung cancer: Efficacy and safety. PMID 40679002 · Pak J Pharm Sci · 2025 The record describes a randomized trial in oncology with a drug intervention and a time-to-event endpoint (PFS). However, the phase is not explicitly stated as Phase III/IIIb or Phase II/III in the provided metadata (title, abstract, publication types, MeSH). The metadata indicates 'needs_review' with 'phase3_evidence_unclear'. Per the adjudication rules, the phase must be explicitly established; it cannot be inferred or assumed. Therefore, the required criterion of phase3_or_definitive cannot be confirmed. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy of opioid-free anesthesia in short-term recovery following laparoscopic-assisted colorectal tumor resection: a randomized trial. PMID 40672749 · Front Oncol · 2025 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| In vitro 3D drug sensitivity testing for patient-derived tumor-like cell clusters and whole-exome sequencing to personalize postoperative treatment: A study protocol for a multicenter randomized controlled trial. PMID 40658653 · PLoS One · 2025 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Biweekly CAPOX versus triweekly CAPOX in the adjuvant therapy of post-surgery CRC: A randomized controlled trial. PMID 40644418 · PLoS One · 2025 The study meets most criteria: it is an oncology, human, randomized trial with a drug intervention and reports a time-to-event efficacy endpoint (3-year DFS) with HR. However, the phase is not explicitly stated in the provided metadata as Phase III/IIIb or Phase II/III (only 'randomized controlled trial' is noted). Additionally, the primary endpoint is safety (thrombocytopenia), while the key secondary endpoint is the efficacy endpoint (DFS). To be eligible, the trial must be explicitly Phase III/IIIb or Phase II/III and the time-to-event endpoint must be the primary or key secondary endpoint of a definitive trial. Without explicit phase confirmation, eligibility cannot be established. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Effects of aerobic exercise on body composition and exerkines in colorectal cancer survivors. PMID 40642656 · Front Sports Act Living · 2025 The record describes a randomized trial of aerobic exercise in colorectal cancer survivors with immune biomarker endpoints. It is eligible for oncology and human criteria, but it is excluded because it lacks a drug intervention and a time-to-event efficacy endpoint. The study is not a Phase III/IIIb or Phase II/III trial and does not report Kaplan-Meier or HR data for OS/PFS/DFS. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A double-blind, placebo-controlled, randomized, multi-centre, phase III study of MLC901 (NeuroAiDTMII) for the treatment of cognitive impairment after mild traumatic brain injury. PMID 40638707 · PLoS One · 2025 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| The PD COMM Process Evaluation: Describing Interventions and Implementation in a UK Pragmatic Randomised Controlled Trial of Speech and Language Therapy for People With Parkinson's-Related Dysarthria. PMID 40637984 · Int J Lang Commun Disord · 2025 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Neoadjuvant chemotherapy with or without metformin in early-stage or locally advanced (non-metastatic) triple negative breast cancer-an open-label phase 2 randomized controlled trial. PMID 40636683 · Front Oncol · 2025 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Electroacupuncture Prevent and Treat Perioperative Cognitive Impairment in Elderly Patients Undergoing Hip Surgery: A Protocol for a Randomized Controlled Trial. PMID 40606589 · J Pain Res · 2025 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Lebrikizumab Improved Itch Symptoms and Reduced Itch Interference on Sleep over 52 Weeks in Patients with Moderate-to-Severe Atopic Dermatitis in Two Phase 3 Trials. PMID 40602386 · Dermatology · 2025 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Efficacy and Safety of SmofKabiven® Versus Hospital-Compounded All-in-One Parenteral Nutrition in Chinese Patients Undergoing Gastrointestinal Surgery: A Multicenter, Randomized, Active-Controlled, Phase III Trial. PMID 40598717 · Nutr Cancer · 2025 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of rimegepant for the acute treatment of migraine in Japan: A dose-ranging, double-blind, randomized controlled trial. PMID 40586377 · Headache · 2025 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Self-reported health and depression among EIRA cohort: a moderated mediation model of sex and perceived social support. PMID 40584072 · Front Psychol · 2025 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Attractive targeted sugar baits for malaria control in western Kenya (ATSB-Kenya) - Effect of ATSBs on epidemiologic and entomologic indicators: A Phase III, open-label, cluster-randomised, controlled trial. PMID 40570028 · PLOS Glob Public Health · 2025 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Ceftobiprole versus ceftriaxone ± linezolid in Community-Acquired Bacterial Pneumonia (CABP): Re-analysis of a randomized, phase 3 study using 2020 FDA guidance. PMID 40554538 · PLoS One · 2025 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Long-Term Symptomatic and Functional Remission with Paliperidone Palmitate 6-Monthly Treatment in Schizophrenia: A 3-Year Post-Hoc Analysis. PMID 40548350 · Neuropsychiatr Dis Treat · 2025 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
|
仅历史库存 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| A digitally enabled home-based wound care program using the PEDALs model: a mixed-methods study protocol. PMID 40547473 · Front Public Health · 2025 方案论文未报告临床试验结果。 |
H
|
仅历史库存 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Integrated Immune Landscape Analysis of RNA Splicing Factor-Mutant AML and Higher risk MDS Treated with Azacitidine ± Durvalumab. PMID 40546817 · Ther Adv Hematol · 2025 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Use of TDCS with proprioceptive exercises to improve gait and balance in visually impaired children and preadolescents: a protocol for randomized clinical trial study. PMID 40538416 · Front Rehabil Sci · 2025 方案论文未报告临床试验结果。 |
H
|
仅历史库存 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Povidone-iodine nasal spray (Nasodine®) for the common cold: a randomized, controlled, double-blind, Phase III clinical trial. PMID 40538402 · Front Med (Lausanne) · 2025 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
|
仅历史库存 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Effectiveness of mucoactives (carbocisteine and hypertonic saline) in addition to usual airway clearance management with usual airway clearance management alone in acute respiratory failure (MARCH): study protocol for a multi-centre 2x2 factorial, randomised, controlled, open-label, Phase 3, pragmatic, clinical and cost-effectiveness trial with internal pilot. PMID 40519627 · NIHR Open Res · 2025 方案论文未报告临床试验结果。 |
H
|
仅历史库存 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Effects of Topical Capsaicin for Chemotherapy-Induced Peripheral Neuropathy (CIPN) Prophylaxis in Oxaliplatin-Treated Cancer Patients: A Double-Blind Randomized Clinical Trial. PMID 40519580 · Adv Biomed Res · 2025 The study is a randomized, double-blind, placebo-controlled trial in cancer patients evaluating a drug (capsaicin) for prevention of chemotherapy-induced peripheral neuropathy. The primary efficacy endpoint is neuropathy grade (ordinal) and symptom severity, which is a toxicity/side-effect outcome, not a time-to-event efficacy endpoint such as OS, PFS, DFS, etc. Therefore, it does not meet the requirement for a Kaplan-Meier or time-to-event primary/key secondary endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Effect of Peer Education on Early Breast Cancer Detection, Health Responsibility, Health Beliefs, Knowledge, and Practices Among University Students. PMID 40518814 · Public Health Nurs · 2025 The study is a randomized controlled trial on early breast cancer detection and education, but it lacks a drug intervention, does not specify a Phase III design, and does not report time-to-event efficacy endpoints like OS or PFS. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Preoperative Radiotherapy Does Not Increase the Risk for Early Complications Following Surgery for Oral Cancer: A Study on Data From the Randomized ARTSCAN 2 Trial. PMID 40515490 · J Otolaryngol Head Neck Surg · 2025 The study is an RCT in oncology, but it lacks a drug-containing intervention (radiotherapy is non-drug) and does not report a primary/key secondary time-to-event efficacy endpoint; therefore, it does not meet all eligibility criteria for the cohort. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Adoptive cellular immunotherapy combined with chemotherapy versus chemotherapy alone in Chinese patients with metastatic colorectal cancer: a cost-effectiveness analysis to inform drug pricing. PMID 40496606 · Front Oncol · 2025 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
S
B
|
严格 v3 独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Effect of Faricimab versus Aflibercept on Hyperreflective Foci in Patients with Diabetic Macular Edema from the YOSEMITE/RHINE Trials. PMID 40496217 · Ophthalmol Sci · 2025 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
|
仅历史库存 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Clinical study outcomes in IgA nephropathy: A systematic literature review and narrative synthesis. PMID 40493692 · PLoS One · 2025 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |